Jean-michel Luccarini
50 Rue De Dijon
Daix, 21121, France
Daix, 21121, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas.
Journal: Nature communications
Published: December 08, 2020
Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models.
Journal: PloS one
Published: October 31, 2019
Inhibition of Interleukin-23-Mediated Inflammation with a Novel Small Molecule Inverse Agonist of RORγt.
Journal: The Journal of pharmacology and experimental therapeutics
Published: March 25, 2019
Discovery of novel quinoline sulphonamide derivatives as potent, selective and orally active RORγ inverse agonists.
Journal: Bioorganic & medicinal chemistry letters
Published: March 05, 2019
Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.
Journal: Journal of medicinal chemistry
Published: February 16, 2018
The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis.
Journal: Hepatology communications
Published: March 17, 2017
Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension.
Journal: Annals of the rheumatic diseases
Published: November 13, 2016
Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.
Journal: Annals of the rheumatic diseases
Published: June 04, 2015
From bradykinin B2 receptor antagonists to orally active and selective bradykinin B1 receptor antagonists.
Journal: Journal of medicinal chemistry
Published: February 29, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026